GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Beneish M-Score
中文

AtriCure (AtriCure) Beneish M-Score : -2.63 (As of Apr. 25, 2024)


View and export this data going back to 2005. Start your Free Trial

What is AtriCure Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.63 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for AtriCure's Beneish M-Score or its related term are showing as below:

ATRC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.88   Med: -2.57   Max: -2.05
Current: -2.63

During the past 13 years, the highest Beneish M-Score of AtriCure was -2.05. The lowest was -2.88. And the median was -2.57.


AtriCure Beneish M-Score Historical Data

The historical data trend for AtriCure's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Beneish M-Score Chart

AtriCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.33 -2.80 -2.51 -2.45 -2.63

AtriCure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.45 -2.69 -2.54 -2.50 -2.63

Competitive Comparison of AtriCure's Beneish M-Score

For the Medical Instruments & Supplies subindustry, AtriCure's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AtriCure's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AtriCure's Beneish M-Score falls into.



AtriCure Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AtriCure for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0176+0.528 * 0.9895+0.404 * 0.8759+0.892 * 1.2084+0.115 * 0.8959
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9057+4.679 * -0.056832-0.327 * 1.0962
=-2.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $52.5 Mil.
Revenue was 106.543 + 98.29 + 100.918 + 93.494 = $399.2 Mil.
Gross Profit was 79.815 + 73.869 + 77.077 + 69.609 = $300.4 Mil.
Total Current Assets was $266.2 Mil.
Total Assets was $613.9 Mil.
Property, Plant and Equipment(Net PPE) was $46.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $14.8 Mil.
Selling, General, & Admin. Expense(SGA) was $253.1 Mil.
Total Current Liabilities was $74.6 Mil.
Long-Term Debt & Capital Lease Obligation was $72.0 Mil.
Net Income was -9.789 + -9.055 + -5.118 + -6.476 = $-30.4 Mil.
Non Operating Income was 0.009 + -0.062 + -0.123 + 0.145 = $-0.0 Mil.
Cash Flow from Operations was 4.03 + 1.522 + 3.011 + -4.079 = $4.5 Mil.
Total Receivables was $42.7 Mil.
Revenue was 88.028 + 83.246 + 84.529 + 74.576 = $330.4 Mil.
Gross Profit was 65.113 + 61.713 + 63.519 + 55.595 = $245.9 Mil.
Total Current Assets was $215.2 Mil.
Total Assets was $585.4 Mil.
Property, Plant and Equipment(Net PPE) was $42.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $11.7 Mil.
Selling, General, & Admin. Expense(SGA) was $231.3 Mil.
Total Current Liabilities was $58.4 Mil.
Long-Term Debt & Capital Lease Obligation was $69.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(52.501 / 399.245) / (42.693 / 330.379)
=0.131501 / 0.129224
=1.0176

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(245.94 / 330.379) / (300.37 / 399.245)
=0.744418 / 0.752345
=0.9895

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (266.246 + 46.759) / 613.932) / (1 - (215.214 + 42.62) / 585.448)
=0.490163 / 0.559595
=0.8759

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=399.245 / 330.379
=1.2084

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(11.71 / (11.71 + 42.62)) / (14.813 / (14.813 + 46.759))
=0.215535 / 0.24058
=0.8959

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(253.138 / 399.245) / (231.272 / 330.379)
=0.634042 / 0.70002
=0.9057

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((71.961 + 74.569) / 613.932) / ((69.076 + 58.392) / 585.448)
=0.238675 / 0.217727
=1.0962

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-30.438 - -0.031 - 4.484) / 613.932
=-0.056832

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AtriCure has a M-score of -2.63 suggests that the company is unlikely to be a manipulator.


AtriCure Beneish M-Score Related Terms

Thank you for viewing the detailed overview of AtriCure's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


AtriCure (AtriCure) Business Description

Traded in Other Exchanges
N/A
Address
7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Executives
Karl S. Dahlquist officer: Chief Legal Officer 7555 INNOVATION WAY, MASON OH 45040
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy officer: Chief Scientific Officer 7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Tonya Austin officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick officer: Chief Financial Officer 7555 INNOVATION WAY, MASON OH 45040
Mark A Collar director 382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith officer: SVP of Sales and Marketing 7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera officer: VP; Product Development 7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky officer: SVP, Mktg & Business Develop 7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein director